Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 13, 2024Journal of Pharmacology and Experimental Therapeutics

GPR55 Antagonist KLS-13019 Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMichael IppolitoHSHajra SohailIBIan Barckhausen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ippolito et al. (2024) studied this question.

synapsesocial.com/papers/68e6a622b6db6435876295cfhttps://doi.org/10.1124/jpet.289.102431
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<b>KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55</b><b>receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats.</b>2024 · 4 citations
  2. 2Knockdown siRNA targeting GPR55 reveals significant differences between the anti- inflammatory actions of KLS-13019 and cannabidiol2024
  3. 3Assessment of an Allosteric Modulator of GIRK 1/2 in Preclinical Models of Cancer-Related Neuropathies to Alleviate Associated Mechanical Allodynia2024
  4. 4Activation of GPR55 alleviates neuropathic pain and chronic inflammation2024 · 3 citations
  5. 5Enhancement of Opioid Analgesia by Positive Allosteric Modulation of the μ-Opioid Receptor in a Rat Model of Chronic Neuropathic Pain2024